Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Sivertsen, Magne Sand ^a   Jørstad, Øystein Kalsnes ^a   Grevys, Algirdas ^a,b   Foss, Stian ^a,b   Moe, Morten Carstens ^a   Andersen, Jan Terje ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; FUSION PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

CHEMISTRY; DRUG FORMULATION; DRUG STABILITY; HUMAN; METABOLISM; STANDARDS; SYRINGE;

DRUG COMPOUNDING; DRUG STABILITY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SYRINGES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85041587703     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-20525-8     Document Type: Article

References (36)

1. Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. The New England journal of medicine 355, 1419-1431, https://doi. org/10. 1056/NEJMoa054481 (2006).
2. Brown, D. M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England journal of medicine 355, 1432-1444, https://doi. org/10. 1056/NEJMoa062655 (2006).
3. Baker, C. W., Jiang, Y. & Stone, T. Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network. Current opinion in ophthalmology 27, 210-216, https://doi. org/10. 1097/ICU. 0000000000000262 (2016).
4. Oellers, P., Grewal, D. S. & Fekrat, S. Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials. Clinical ophthalmology 10, 411-418, https://doi. org/10. 2147/OPTH. S98853 (2016).
5. Group, C. R. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England journal of medicine 364, 1897-1908, https://doi. org/10. 1056/NEJMoa1102673 (2011).
6. Berg, K. et al. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results. Ophthalmology 123, 51-59, https://doi. org/10. 1016/j. ophtha. 2015. 09. 018 (2016).
7. Chakravarthy, U. et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382, 1258-1267, https://doi. org/10. 1016/S0140-6736(13)61501-9 (2013).
8. Wells, J. A. et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology 123, 1351-1359, https://doi. org/10. 1016/j. ophtha. 2016. 02. 022 (2016).
9. McCannel, C. A. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 31, 654-661, https://doi. org/10. 1097/IAE. 0b013e31820a67e4 (2011).
10. Merani, R. & Hunyor, A. P. Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: A comprehensive review. International journal of retina and vitreous 1, 9, https://doi. org/10. 1186/s40942-015-0010-y (2015).
11. Papadopoulos, N. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171-185, https://doi. org/10. 1007/s10456-011-9249-6 (2012).
12. Balaratnasingam, C., Dhrami-Gavazi, E., McCann, J. T., Ghadiali, Q. & Freund, K. B. Aflibercept: A review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clinical ophthalmology 9, 2355-2371, https://doi. org/10. 2147/OPTH. S80040 (2015).
13. VanderBeek, B. L., Bonaffini, S. G. & Ma, L. Association of compounded bevacizumab with postinjection endophthalmitis. JAMA ophthalmology 133, 1159-1164, https://doi. org/10. 1001/jamaophthalmol. 2015. 2556 (2015).
14. Subhi, Y., Kjer, B. & Munch, I. C. Prefilled syringes for intravitreal injection reduce preparation time. Danish medical journal 63 (2016).
15. Ward, E. S. & Ober, R. J. Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol 103, 77-115, https://doi. org/10. 1016/S0065-2776(09)03004-1 (2009).
16. Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7, 715-725, https://doi. org/10. 1038/ nri2155 (2007).
17. Gao, X. et al. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation. Journal of pharmaceutical sciences 104, 368-377, https://doi. org/10. 1002/jps. 24136 (2015).
18. Stracke, J. et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. mAbs 6, 1229-1242, https://doi. org/10. 4161/mabs. 29601 (2014).
19. Kim, H., Robinson, S. B. & Csaky, K. G. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Molecular vision 15, 2803-2812 (2009).
20. Bakri, S. J. et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 26, 519-522, https://doi. org/10. 1097/01. iae. 0000225354. 92444. 7a (2006).
21. Paul, M. et al. Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration. Annales pharmaceutiques francaises 70, 139-154, https://doi. org/10. 1016/j. pharma. 2012. 03. 006 (2012).
22. Pereboom, M. et al. Stability assessment of repackaged bevacizumab for intravitreal administration. International journal of pharmaceutical compounding 19, 70-72 (2015).
23. Phasukkijwatana, N., Tanterdtham, J. & Lertpongparkpoom, D. Stability of Bevacizumab Divided in Multiple Doses for Intravitreal Injection. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 98, 798-803 (2015).
24. Signorello, L. et al. Quantification, microbial contamination, physico-chemical stability of repackaged bevacizumab stored under different conditions. Current pharmaceutical biotechnology 15, 113-119 (2014).
25. Yannuzzi, N. A. et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA ophthalmology 133, 32-39, https://doi. org/10. 1001/jamaophthalmol. 2014. 3591 (2015).
26. Grisanti, S. & Tura, A. Qualitative differences between ranibizumab from original and ready to use syringes. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 107, 1123-1132, https://doi. org/10. 1007/s00347-010-2299-0 (2010).
27. Cao, S., Cui, J., Matsubara, J. & Forooghian, F. Long-term in vitro functional stability of compounded ranibizumab and aflibercept. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 52, 273-276, https://doi. org/10. 1016/j. jcjo. 2016. 11. 012 (2017).
28. Mansour, A. M., Al-Ghadban, S. I., Yunis, M. H. & El-Sabban, M. E. Ziv-aflibercept in macular disease. The British journal of ophthalmology 99, 1055-1059, https://doi. org/10. 1136/bjophthalmol-2014-306319 (2015).
29. Andrade, G. C. et al. Intravitreal injections of ziv-aflibercept for diabetic macular edema: A Pilot Study. Retina 36, 1640-1645, https://doi. org/10. 1097/IAE. 0000000000001000 (2016).
30. Braimah, I. Z., Agarwal, K., Mansour, A., Chhablani, J. & Ziv-aflibercept Study, G. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration. The British journal of ophthalmology, https://doi. org/10. 1136/bjophthalmol-2017-310318 (2017).
31. Paulose, R., Chhablani, J., Dedhia, C. J., Stewart, M. W. & Mansour, A. M. Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion. Clinical ophthalmology 10, 1853-1858, https://doi. org/10. 2147/OPTH. S116343 (2016).
32. Videkar, C., Kapoor, A., Chhablani, J. & Narayanan, R. Ziv-aflibercept: A novel option for the treatment of polypoidal choroidal vasculopathy. BMJ Case Rep 2015, https://doi. org/10. 1136/bcr-2015-212988 (2015).
33. European Commission. The Rules Governing Medicinal Products in the European Union; Volume 4; EU Guidelines to Good Manufacturing Practice; Medicinal Products for Human and Veterinary Use; Annex; Manufacture of Sterile Medicinal Products (corrected version). https://ec. europa. eu/health/documents/eudralex/vol-4-en (2008).
34. International Organization for Standardization. ISO 14644-1 Cleanrooms and associated controlled environments-Part 1: Classification of air cleanliness by particle concentration. https://www. iso. org/standard/53394. html (2015).
35. Andersen, J. T. et al. Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. The FEBS journal 275, 4097-4110, https://doi. org/10. 1111/j. 1742-4658. 2008. 06551. x (2008).
36. Niesen, F. H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nature protocols 2, 2212-2221, https://doi. org/10. 1038/nprot. 2007. 321 (2007).